

## **Christoph Brönnimann**

**Swiss (born 1966)**

**CEO (Chief Executive Officer)**

**Member of the Executive Management Board since September 2019**

Christoph Brönnimann is the newly appointed CEO of Medartis.

He has a proven track record of successes in managing various international corporations in the medical technology field. In 2005, he joined Synthes where he managed the global integration of Stratec and Mathys and held various leadership positions for larger organizational units. Among others, he was responsible for the global quality management and new product approvals, as well as overseeing international logistics. He later became the General Manager of Synthes Switzerland.

At Johnson & Johnson - following their acquisition of Synthes - Christoph Brönnimann was first responsible for DePuy Synthes Germany and then headed the Johnson & Johnson ONE Medical Device unit for Germany, Switzerland and Austria as a member of the Medical Devices Europe Executive Board. The medical devices businesses of Johnson & Johnson comprise of the Trauma and Orthopedics of DePuy Synthes, the general surgery business of Ethicon, as well as the cardiology and specialty surgery business of Biosense Webster, Cerenovus and Mentor.

Earlier in his career, he held managerial positions in Mergers & Acquisitions Advisory and Corporate Finance at PwC. In 1996, he joined Roche and worked in marketing and product management in the US until 2000.

Christoph Brönnimann has a PhD in chemistry from ETH Zurich and completed a General Management Program at the Harvard Business School.

He enriches Medartis with his proven expertise in the field of medical technology, his strong leadership skills, his global network of experts, his reliability and his pragmatic and efficient style.